ELEVANCE HEALTH ($ELV) is expected to release its quarterly earnings data on Thursday, July 17th before market open, per Finnhub. Analysts are expecting revenue of $48,716,894,722 and earnings of $9.29 per share.
You can see Quiver Quantitative's $ELV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ELEVANCE HEALTH Insider Trading Activity
ELEVANCE HEALTH insiders have traded $ELV stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:
- MARK KAYE (EVP & CFO) sold 4,588 shares for an estimated $1,949,074
- CHARLES MORGAN JR KENDRICK (EVP & President, Commercial) sold 3,504 shares for an estimated $1,388,635
- RONALD W PENCZEK (CAO & Controller) sold 443 shares for an estimated $183,902
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ELEVANCE HEALTH Hedge Fund Activity
We have seen 793 institutional investors add shares of ELEVANCE HEALTH stock to their portfolio, and 699 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 1,675,257 shares (+43.2%) to their portfolio in Q1 2025, for an estimated $728,669,784
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,475,499 shares (-13.9%) from their portfolio in Q1 2025, for an estimated $641,783,045
- GAMMA INVESTING LLC removed 1,471,569 shares (-99.8%) from their portfolio in Q2 2025, for an estimated $572,381,478
- BANK OF AMERICA CORP /DE/ added 878,855 shares (+66.3%) to their portfolio in Q1 2025, for an estimated $382,266,770
- BLACKROCK, INC. added 868,829 shares (+4.3%) to their portfolio in Q1 2025, for an estimated $377,905,861
- ORBIS ALLAN GRAY LTD added 680,228 shares (+31.4%) to their portfolio in Q1 2025, for an estimated $295,871,970
- VANGUARD GROUP INC added 666,534 shares (+3.1%) to their portfolio in Q1 2025, for an estimated $289,915,628
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ELEVANCE HEALTH Government Contracts
We have seen $297,071,421 of award payments to $ELV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PART A/PART B MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) JURISDICTION K (JK): $100,651,859
- NEXT GENERATION DESKTOP IGF::OT::IGF: $90,487,661
- J6 A/B MAC SERVICES: $86,352,834
- SPARC WILL BE THE MAJOR CONTRACT VEHICLE FOR CMS IT SYSTEMS AND SUPPORT HHS OPDIVS CAN ALSO MAKE USE OF SPA...: $9,953,079
- INNOVATION PAYMENT CONTRACTOR (IPC) CONTRACT AWARD: $4,219,631
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ELEVANCE HEALTH Congressional Stock Trading
Members of Congress have traded $ELV stock 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ELV stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 04/29 and 1 sale worth up to $15,000 on 05/30.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $50,000 on 05/15.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 1 purchase worth up to $50,000 on 02/24 and 1 sale worth up to $50,000 on 05/12.
- REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 04/11.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 03/10.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ELEVANCE HEALTH Analyst Ratings
Wall Street analysts have issued reports on $ELV in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 07/15/2025
- Barclays issued a "Overweight" rating on 07/09/2025
- Truist Securities issued a "Buy" rating on 06/09/2025
- RBC Capital issued a "Outperform" rating on 06/04/2025
- Argus Research issued a "Buy" rating on 04/25/2025
- Guggenheim issued a "Buy" rating on 04/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/23/2025
To track analyst ratings and price targets for ELEVANCE HEALTH, check out Quiver Quantitative's $ELV forecast page.
ELEVANCE HEALTH Price Targets
Multiple analysts have issued price targets for $ELV recently. We have seen 10 analysts offer price targets for $ELV in the last 6 months, with a median target of $484.5.
Here are some recent targets:
- Stephen Baxter from Wells Fargo set a target price of $400.0 on 07/15/2025
- A.J. Rice from UBS set a target price of $484.0 on 07/14/2025
- Andrew Mok from Barclays set a target price of $434.0 on 07/09/2025
- David Macdonald from Truist Securities set a target price of $500.0 on 06/09/2025
- Ben Hendrix from RBC Capital set a target price of $478.0 on 06/04/2025
- David Toung from Argus Research set a target price of $465.0 on 04/25/2025
- Jason Cassorla from Guggenheim set a target price of $518.0 on 04/23/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
